Catalent (CTLT) Revenue & Revenue Breakdown
Catalent Revenue Highlights
Latest Revenue (Y)
$4.38B
Latest Revenue (Q)
$1.07B
Main Segment (Y)
Biologics
Main Geography (Y)
Total Catalent before inter-segment revenue elimination
Catalent Revenue by Period
Catalent Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $4.38B | 2.46% |
| 2023-06-30 | $4.28B | -11.43% |
| 2022-06-30 | $4.83B | 20.76% |
| 2021-06-30 | $4.00B | 29.21% |
| 2020-06-30 | $3.09B | 22.89% |
| 2019-06-30 | $2.52B | 2.22% |
| 2018-06-30 | $2.46B | 18.70% |
| 2017-06-30 | $2.08B | 12.30% |
| 2016-06-30 | $1.85B | 0.94% |
| 2015-06-30 | $1.83B | 0.17% |
| 2014-06-30 | $1.83B | 1.52% |
| 2013-06-30 | $1.80B | 6.22% |
| 2012-06-30 | $1.69B | 10.64% |
| 2011-06-30 | $1.53B | - |
Catalent generated $4.38B in revenue during NA 2024, up 2.46% compared to the previous quarter, and up 173.99% compared to the same period a year ago.
Catalent Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.07B | 4.88% |
| 2023-12-31 | $1.02B | 4.28% |
| 2023-09-30 | $982.00M | -8.05% |
| 2023-06-30 | $1.07B | 2.99% |
| 2023-03-31 | $1.04B | -9.75% |
| 2022-12-31 | $1.15B | 12.43% |
| 2022-09-30 | $1.02B | -22.16% |
| 2022-06-30 | $1.31B | 3.14% |
| 2022-03-31 | $1.27B | 4.60% |
| 2021-12-31 | $1.22B | 18.73% |
| 2021-09-30 | $1.02B | -13.72% |
| 2021-06-30 | $1.19B | 12.79% |
| 2021-03-31 | $1.05B | 15.65% |
| 2020-12-31 | $910.80M | 7.70% |
| 2020-09-30 | $845.70M | -10.75% |
| 2020-06-30 | $947.60M | 24.59% |
| 2020-03-31 | $760.60M | 5.43% |
| 2019-12-31 | $721.40M | 8.53% |
| 2019-09-30 | $664.70M | -8.41% |
| 2019-06-30 | $725.70M | 17.52% |
| 2019-03-31 | $617.50M | -0.88% |
| 2018-12-31 | $623.00M | 12.90% |
| 2018-09-30 | $551.80M | -19.48% |
| 2018-06-30 | $685.30M | 9.14% |
| 2018-03-31 | $627.90M | 3.56% |
| 2017-12-31 | $606.30M | 11.47% |
| 2017-09-30 | $543.90M | -11.83% |
| 2017-06-30 | $616.90M | 15.83% |
| 2017-03-31 | $532.60M | 10.11% |
| 2016-12-31 | $483.70M | 9.38% |
| 2016-09-30 | $442.20M | -16.91% |
| 2016-06-30 | $532.20M | 21.51% |
| 2016-03-31 | $438.00M | -3.72% |
| 2015-12-31 | $454.90M | 7.54% |
| 2015-09-30 | $423.00M | -17.08% |
| 2015-06-30 | $510.10M | 14.22% |
| 2015-03-31 | $446.60M | -2.02% |
| 2014-12-31 | $455.80M | 8.96% |
| 2014-09-30 | $418.30M | -19.50% |
| 2014-06-30 | $519.60M | 14.68% |
| 2014-03-31 | $453.10M | 2.81% |
| 2013-12-31 | $440.70M | 6.37% |
| 2013-09-30 | $414.30M | -17.99% |
| 2013-06-30 | $505.20M | 13.02% |
| 2013-03-31 | $447.00M | 2.50% |
| 2012-12-31 | $436.10M | 5.85% |
| 2012-09-30 | $412.00M | - |
Catalent generated $1.07B in revenue during Q3 2024, up 4.88% compared to the previous quarter, and up 93.47% compared to the same period a year ago.
Catalent Revenue Breakdown
Catalent Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Jun 22 | Jun 21 | Jun 20 | Jun 19 | Jun 18 |
|---|---|---|---|---|---|
| Total Catalent before inter-segment revenue elimination | $400.00M | $4.02B | $3.10B | $2.56B | - |
| Softgel and Oral Technologies | $1.25B | $1.01B | $1.06B | - | - |
| Oral and Specialty Delivery | $650.00M | $686.00M | $675.90M | - | - |
| Biologics | $2.55B | $1.93B | $1.02B | - | - |
| Clinical Supply Services | $400.00M | - | - | - | $430.40M |
| Softgel Technologies | $1.25B | $872.10M | $917.30M | - | - |
| Oral Drug Delivery | $650.00M | $619.90M | $573.90M | - | - |
| Biologics and Specialty Drug Delivery | - | - | - | $742.10M | $601.90M |
Catalent's latest annual revenue breakdown by segment (product or service), as of Jun 22: Biologics (35.70%), Softgel and Oral Technologies (17.45%), Softgel Technologies (17.45%), Oral and Specialty Delivery (9.10%), Oral Drug Delivery (9.10%), Total Catalent before inter-segment revenue elimination (5.60%), and Clinical Supply Services (5.60%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaConsumerHealth | $613.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Biologics | $461.00M | $438.00M | $448.00M | $475.00M | $580.00M | $523.00M | $667.00M | $698.00M | $638.00M | $546.00M | $603.30M | $543.70M | $403.90M | - | - | - | - | - | - | - |
| Total Catalent before inter-segment revenue elimination | $663.00M | $651.00M | $616.00M | $1.04B | $1.15B | $1.02B | $1.31B | $1.28B | $1.22B | $1.03B | $1.19B | $1.06B | $913.90M | $849.20M | $951.30M | $762.60M | $724.20M | $669.50M | $735.00M | $626.10M |
| Clinical Supply Services | - | - | - | - | - | - | $104.00M | - | - | - | $104.80M | - | - | - | $83.60M | - | - | - | $85.10M | - |
| Softgel Technologies | - | - | - | - | - | - | - | $324.00M | $329.00M | $243.00M | $243.70M | $246.60M | $221.10M | $242.30M | $267.90M | $263.70M | $244.70M | $214.50M | - | - |
| Oral Drug Delivery | - | - | - | - | - | - | - | $154.00M | $156.00M | $146.00M | $171.70M | $169.90M | $158.30M | $181.40M | $143.20M | $132.60M | $174.10M | $161.70M | - | - |
| Biologics and Specialty Drug Delivery | - | - | - | - | - | - | - | - | - | - | - | - | - | $377.10M | $250.00M | $225.20M | $188.60M | $231.10M | $172.10M | - |
Catalent's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Total Catalent before inter-segment revenue elimination (38.17%), PharmaConsumerHealth (35.29%), and Biologics (26.54%).
Catalent Revenue Breakdown by Country
Annual Revenue by Country
| Country | Jun 22 | Jun 21 | Jun 20 | Jun 19 | Jun 18 |
|---|---|---|---|---|---|
| Clinical Supply Services | - | - | - | - | - |
| Europe | $1.51B | $1.34B | $976.10M | $842.10M | $897.80M |
| UNITED STATES | $3.11B | $2.46B | $1.22B | - | - |
| Total Catalent before inter-segment revenue elimination | $4.84B | - | - | - | - |
| Softgel and Oral Technologies | $1.25B | - | - | - | - |
| Oral and Specialty Delivery | $650.00M | - | - | - | - |
| Biologics | $2.55B | - | - | - | - |
| North America | - | - | $1.82B | $1.32B | - |
| Rest of World | - | - | - | - | $415.30M |
Catalent's latest annual revenue breakdown by geography, as of Jun 22: Total Catalent before inter-segment revenue elimination (34.84%), UNITED STATES (22.36%), Biologics (18.33%), Europe (10.83%), Softgel and Oral Technologies (8.96%), and Oral and Specialty Delivery (4.67%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $690.00M | $653.00M | $645.00M | $685.00M | $734.00M | $697.00M | $847.00M | $793.00M | $630.00M | $670.00M | $535.30M | $516.90M | $606.30M | $438.90M | $414.70M | $362.30M | $403.40M | $318.40M | - | - |
| Europe | $345.00M | $324.00M | $274.00M | $306.00M | $356.00M | $274.00M | $411.00M | $373.00M | $370.00M | $351.00M | $388.20M | $344.90M | $326.40M | $281.40M | $286.00M | $258.70M | $221.40M | $210.10M | $232.20M | $200.80M |
| Biologics | - | - | - | - | $580.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Catalent before inter-segment revenue elimination | - | - | - | - | $1.15B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Catalent's latest quarterly revenue breakdown by geography, as of Mar 24: North America (66.67%), and Europe (33.33%).
CTLT Revenue FAQ
What is Catalent’s yearly revenue?
Catalent's yearly revenue for 2024 was $4.38B, representing an increase of 2.46% compared to 2023. The company's yearly revenue for 2023 was $4.28B, representing a decrease of -11.43% compared to 2022. CTLT's yearly revenue for 2022 was $4.83B, representing an increase of 20.76% compared to 2021.
What is Catalent’s quarterly revenue?
Catalent's quarterly revenue for Q3 2024 was $1.07B, a 4.88% increase from the previous quarter (Q2 2024), and a 3.57% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.02B, a 4.28% increase from the previous quarter (Q1 2024), and a -10.88% decrease year-over-year (Q2 2023). CTLT's quarterly revenue for Q1 2024 was $982M, a -8.05% decrease from the previous quarter (Q4 2023), and a -3.91% decrease year-over-year (Q1 2023).
What is Catalent’s revenue growth rate?
Catalent's revenue growth rate for the last 3 years (2022-2024) was -9.26%, and for the last 5 years (2020-2024) was 41.58%.
What are Catalent’s revenue streams?
Catalent's revenue streams in n 22 are Total Catalent before inter-segment revenue elimination, Softgel and Oral Technologies, Oral and Specialty Delivery, Biologics, Clinical Supply Services, Softgel Technologies, and Oral Drug Delivery. Total Catalent before inter-segment revenue elimination generated $400M in revenue, accounting 5.60% of the company's total revenue, down -90.04% year-over-year. Softgel and Oral Technologies generated $1.25B in revenue, accounting 17.45% of the company's total revenue, up 23.12% year-over-year. Oral and Specialty Delivery generated $650M in revenue, accounting 9.10% of the company's total revenue, down -5.25% year-over-year. Biologics generated $2.55B in revenue, accounting 35.70% of the company's total revenue, up 32.21% year-over-year. Clinical Supply Services generated $400M in revenue, accounting 5.60% of the company's total revenue Softgel Technologies generated $1.25B in revenue, accounting 17.45% of the company's total revenue, up 42.87% year-over-year. Oral Drug Delivery generated $650M in revenue, accounting 9.10% of the company's total revenue, up 4.86% year-over-year.
What is Catalent’s main source of revenue?
For the fiscal year ending Jun 22, the largest source of revenue of Catalent was Biologics. This segment made a revenue of $2.55B, representing 35.70% of the company's total revenue.